Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC

Outcome improvement in patients with driver-gene-negative advanced non-small cell lung cancer (NSCLC) has been significantly enhanced through targeting the immune system, specifically the PD-L1/PD-1 axis. Nevertheless, only a subset of patients with advanced NSCLC may derive benefits from immuno-mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yiyi, Chau, Yi-Fung, Bai, Hua, Wu, Xinyu, Duan, Jianchun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572984/
https://www.ncbi.nlm.nih.gov/pubmed/37833968
http://dx.doi.org/10.3390/ijms241914521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572984/
https://www.ncbi.nlm.nih.gov/pubmed/37833968
http://dx.doi.org/10.3390/ijms241914521

Ejemplares similares